ROSEVILLE, Minn .– (KEV LAG LUAM HLUAS) - #Cdiff –Rebiotix, Inc, lub tuam txhab Ferring Pharmaceuticals, tau tshaj tawm hnub no tias ob tug tswv cuab ntawm lawv pawg thawj coj laus, Dr. Ken Blount, Tus Thawj Coj Saib Xyuas Kev Tshawb Fawb thiab Dr. Edward Burd, Tus Thawj Tuav Tswj Kev Cai, yuav koom nrog cov kev sib tham tseem ceeb hauv 2019 Microbiome Zog - Kev Tshawb Fawb Txog Tshuaj Txhim Kho . Lub rooj sib tham ib xyoos ib zaug yuav muaj rau lub Rau Hli 26-28 hauv Boston, MA.
Tus neeg tsim qauv hauv daim teb microbiome, Dr. Blount yuav hais lus nyob rau ntawm Microbiome Industry Leaders panel, uas nws yuav qhia txog cov kev tshawb fawb txog kev tshawb fawb thiab kev tsim khoom hauv pawg, txuas ntxiv mus los ntawm Rebiotix txoj kev soj ntsuam thiab tshawb xyuas microbiome hauv lub tuam txhab kev tsim kho tshiab, kev tshawb nrhiav. MRT ™ platform tshuaj.
Ntxiv rau ntawm pab pawg, Dr. Blount yuav tshaj tawm txog Rebiotix's cov tho kev Microbiome Health Index MH (MHI). Cov lus hais yuav tsom mus rau lub tuam txhab cov kev nce qib hauv kev tsim cov txheej txheem los ua ib qho kev ntsuas rau kev kho kom rov zoo li qub ntawm cov neeg mob microbiome cov zej zog tom qab kev kho mob nrog ib qho ntawm lub tuam txhab kev tshawb nrhiav MRT cov qauv. Tam sim no, muaj ob daim ntawv cog lus hauv kev kho mob hauv chaw kho mob - tus thawj coj sib tw, RBX2660, yog kev tso kua ua kua hauv Phase 3; RBX7455, qhov kev tshawb nrhiav, thawj-ntawm-nws-zoo lyophilized, tsis yog-khov, chav-ntsuas qhov ncauj tshuaj ntsiav ruaj khov tsim. Ob qho kev tsim qauv tam sim no yog tsom rau txo qis dua Clostridioides difficile (C. diff) hauv cov neeg laus.
"Nws yog qhov zoo siab los koom rau hauv ib qho kev tshwm sim uas qhia txog kev nrhav tshiab uas tau siv lub zog ntawm lub microbiome. Kuv zoo siab uas tau koom nrog Pawg Thawj Coj Kev Lag Luam ntawm Microbiome Kev Koom Tes los koom nrog lwm tus tub ceev xwm hauv txoj haujlwm, " Dr. Blount. "Nws yog cov xwm txheej zoo li no uas ua rau peb tuaj sib koom ua ke, sib qhia tswv yim thiab ua kom lub neej yav tom ntej kev tuaj yeem ua raws li cov kev kho cov kab mob microbiome."
Dhau ntawm kev tshawb fawb thiab chaw kho mob tshiab hauv qeb, qhov chaw tswj hwm kev coj noj coj ua rau kev kho mob microbiota tseem muaj zuj zus. Thaum pib sau tseg los ntawm Asmeskas Cov Khoom Noj thiab Tshuaj (FDA) hauv xyoo 2013, cov qauv ntxiv tshwj xeeb rau fecal microbiota kev hloov pauv (FMT) yog xav pom nyob rau yav tom ntej thiab txuas ntxiv ua qhov laj thawj ntawm kev sib tham. Txhawm rau hais txog qhov kev tsim kho tshiab tam sim no thiab cuam tshuam rau thaj teb, Dr. Burd yuav yog tus saib xyuas Lub Tsev Cov Txheej Txheem Kom Txhim Kho rau Microbiome-based Therapeutics vaj huam sib luag thaum lub rooj sib tham. Lub vaj huam sib luag yuav hais txog cov kev loj hlob ntawm cov khoom lag luam loj, suav nrog kev sim pub khoom, cov yam ntxwv ntawm cov khoom, thiab cov txheej txheem thoob ntiaj teb zoo nkauj rau cov chav kawm tawm ntawm cov khoom lag luam no.
Dr. Burd tau hais tias , "Nws yog ib qho tseem ceeb uas cov ua kis las hauv thaj chaw no tsom rau kev tsim cov khoom lag luam zoo thiab cov txheej txheem zoo rau cov neeg mob peb tau txais kev pab," "Nrog cov neeg sawv cev los ntawm cov tuam txhab microbiome tseem ceeb thiab lub cev muaj cai tau tshaj tawm cov lus tawm tswv yim txog cov ncauj lus tseem ceeb no, peb tuaj yeem txuas ntxiv hais txog qhov xav tau los ntawm kev saib xyuas kev tswj hwm thiab ua tib zoo soj ntsuam thaum muaj kev nyab xeeb rau cov neeg mob."